The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Choosing the right targeted partner for standard therapy in second-line follicular lymphoma
In this video, Benoit Tessoulin, MD, PhD, Nantes University Hospital Center, Nantes, France, briefly discusses the current approach to treatment selection in second-line follicular lymphoma. He notes that the landscape has evolved beyond lenalidomide plus rituximab (R-squared), with options now including combinations of R-squared with the antibodies tafasitamab or epcoritamab, and potentially CAR T-cell therapies in the future, although approvals for the latter are currently limited to third-line treatment. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
That’s a fuzzy field for now. So what we can see is that we come from R-squared, and R-squared is kind of over. So you are left with two options, combining R-squared plus something, which is either tafasitamab or epcoritamab now. And on a broad view, epcoritamab is suitable for most of the patients, but maybe that tafasitamab has a way forward to, maybe for some more comorbid patients or those who don’t want some, you know, the ramp-up sessions, et cetera...
That’s a fuzzy field for now. So what we can see is that we come from R-squared, and R-squared is kind of over. So you are left with two options, combining R-squared plus something, which is either tafasitamab or epcoritamab now. And on a broad view, epcoritamab is suitable for most of the patients, but maybe that tafasitamab has a way forward to, maybe for some more comorbid patients or those who don’t want some, you know, the ramp-up sessions, et cetera. And regarding the CAR-T cells, as far as I know, no country has been approved in second line – we have data in second line but the approval is only for the third line, so it will be a natural sequence over time to get to the CAR-T cells afterwards.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Advisory/Consultancy: AbbVie, Ascentage, AstraZeneca, BeiGene, Genmab, Janssen, Lilly, Roche; Travel Accommodation: AbbVie, Kite Gilead, AstraZeneca, Roche, Janssen, Lilly.
